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Multivalent helix mimetics for PPI-inhibition†
Anna Barnard,a,b Jennifer A. Miles,a,b George M. Burslem,a,b Amy M. Barkerb,c and
Andrew J. Wilson*a,b
The exploitation of multivalent ligands for the inhibition of protein–protein interactions has not yet been
explored as a supramolecular design strategy. This is despite the fact that protein–protein interactions
typically occur within the context of multi-protein complexes and frequently exploit avidity effects or co-
operative binding interactions to achieve high affinity interactions. In this paper we describe preliminary
studies on the use of a multivalent N-alkylated aromatic oligoamide helix mimetic for inhibition of p53/
hDM2 and establish that protein dimerisation is promoted, rather than enhanced binding resulting from a
higher effective concentration of the ligand.
Introduction
Protein–protein interactions (PPIs) regulate all essential bio-
logical processes and are frequently implicated in the develop-
ment and progression of disease.1 As targets for molecular
recognition, however, PPIs do not conform to conventional
models used in drug design in that they are mediated by shal-
lower surfaces with spatially distinct non-covalent contacts
rather than the traditional lock and key model of biomolecular
protein recognition.2,3 Therefore, PPIs represent an “ultimate
challenge” in terms of complexity for supramolecular design.4
Several different approaches have been applied that exploit
scaffolds that project recognition groups over a large area5–15
and/or target specific hot-spot residues on the surface.16,17 A
particularly fertile avenue of investigation has concerned the
development of secondary structure mimetics;18 α-helices are
the most abundant secondary structure found in proteins and
are frequently found at the interface of PPIs.19 α-Helix
mimetics20–25 are designed to match the spatial arrange-
ment of key binding residues from the helix involved in the
interaction.18 We26–30 and others31–33 have developed several
types of aromatic oligoamide helix mimetics34 with the
binding groups attached to the 3O-,29,35 2O-36 and N-30,37 posi-
tions on the aromatic building blocks notably for the purposes
of p53/hDM2 inhibition.28–30 This PPI is a key regulator of
genomic stability and, as such, is of significant interest in the
development of cancer treatments.38,39 p53 binds to hDM2
through its helical N-terminal transactivation domain. The
interaction is mainly controlled by three key ‘hot-spot’ resi-
dues; Phe19, Trp23 and Leu26.40 hDM2 and its partner hDMX
act as negative regulators by blocking the transcriptional func-
tion of p53 and in the case of hDM2, through its ubiquitin
ligase function which tags p53 for degradation by the protea-
some (Fig. 1a).41 The process by which this occurs at the mole-
cular level is complex, however what is clear is that
ubiquitination is promoted by the formation of
hDM2 homodimers and heterodimers (with hDMX), through
their respective RING domains.42 Moreover, a recent study by
the Roche group revealed that hDM2 and hDMX could be
induced to form dimers, by a small molecule that spans the
p53 binding site of two hDM2(X) monomers (Fig. 1b).43 This
inspired the current study – we hypothesized that the use of
multivalent44 helix mimetics might lead to co-operative
binding properties either through the avidity resulting from
chemically induced dimerisation of the target protein or the
higher effective ligand concentration afforded by the proximity
of additional covalently tethered copies of the protein-binding
ligand (Fig. 1c).45 Multivalent ligands have been utilised for
binding to a multitude of different biological targets includ-
ing, toxins,46 heparin,47 DNA,48,49 β-tryptase50 and of particular
note for foldamers, amyloid oligomers.51 Similarly, palindro-
mic ligands have been utilised to inhibit amyloid assembly e.g.
by stabilizing transthyretin tetramerization52,53 but not for
inhibition of protein–protein interactions (PPIs). Of additional
note, a number of dimeric helix mimetics have previously
been reported.54,55 Herein we describe the synthesis of a
dimeric N-alkylated aromatic oligoamide trimer and illustrate
its ability to promote the inhibition of the p53/hDM2 inter-
action by dimerization/aggregation.
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Results and discussion
Synthesis of a divalent oligobenzamide
To obtain a divalent helix mimetic we employed the ‘click’
chemistry methodology for the synthesis of modified aromatic
oligoamides recently reported by our group.56 A known N-alkyl-
ated inhibitor 1 of the p53/hDM2 interaction possessing phenyl,
napthyl and isopropyl side chains to recapitulate the hot-spot
residues of p53, was synthesised, functionalised with an alkyne,
on solid-phase using an automated microwave peptide synthesi-
ser. Once cleaved from the resin, the trimer was subjected to
standard ‘click’ chemistry reaction conditions with a commer-
cially available ethylene glycol di-azide (Scheme 1). After
removal of the copper catalyst, the dimer 2 was isolated in good
yield and purity. The equivalent monovalent trimer 1 was also
synthesised using previously published methods.37
Inhibition of p53/hDM2
With the divalent mimetic in hand, we sought to determine if
the increased valency would lead to an improvement in the
inhibition of the p53/hDM2 interaction. We employed a fluo-
rescence anisotropy competition assay whereby increasing con-
centrations of ligand 1 and 2 were used displace a fluorescein-
labelled p53 peptide from the hDM2 binding cleft. The
observed decrease in anisotropy was used to determine IC50
values (Fig. 2). Unfunctionalised monovalent trimer 1 was
observed to act as a low μM inhibitor of the p53/hDM2 inter-
action (IC50 = 12.3 ± 0.4 µM). When compared against the diva-
lent mimetic 2 a 2-fold improvement in inhibition was observed
(IC50 = 6.3 ± 0.4 µM). However, as the effective concentration of
binding groups is doubled this indicates an absence of positive
cooperativity. The most likely cause of such an observation is
that dimer 2 simultaneously interacts with two molecules of
hDM2, but without the benefit of additional intermolecular
interactions between the two proteins molecules.
Molecular modelling
To assess if divalent inhibitor 2 was capable of simultaneous
interaction with two copies of hDM2 we carried out a series of
rudimentary modelling experiments. A series of conformers
were generated from the structure of mimetic 2, from which
an extended conformation was selected and each copy of the
hDM2 binding pharmacophore was docked into the binding
site of hDM2 taken from the crystal structure (Fig. 3). The
resultant model indicated no steric clash between the two
protein molecules, despite the ethylene glycol linker not adopt-
ing a fully extended conformation.
Protein assembly
To obtain experimental evidence of protein assembly we ran a
Native PAGE gel (Fig. 4) of hDM2 both alone (lane 1) and in
the presence of either the monovalent ligand 1 (lanes 2–4) or
divalent ligand 2 (lanes 5–7). The gel clearly indicates a differ-
ence in the mobility of the protein in the presence of the di-
valent trimer 2, consistent with an increase in size. In contrast
no such change occurred for monovalent mimetic 1. We then
sought to gain additional more quantitative evidence of
protein aggregation. To this end, sedimentation velocity
analytical centrifugation (svAUC) was performed on hDM2
both with and without DMSO and in the presence of com-
pounds 1 and 2 at a 1 : 4 ratio of protein: ligand (Fig. 5).
In the sample of hDM2 alone a clear peak was observed
corresponding to the approximate molecular weight of the
protein. Importantly, the peak was not perturbed by the pres-
Fig. 1 Multivalent interactions of p53 and hDM2 (a) overview of p53
signalling pathway illustrating how hDM2(X) dimerisation enhances ubi-
quitination of p53. (b) X-ray structure of a small molecule inducer of
hDM2 dimerisation (PDB ID: 3VBG). (c) Schematic depicting possible
consequences of multivalent inhibition of p53/hDM2 (i) inhibition
enhances hDM2 dimerization by additional intermolecular hDM2 con-
tacts or (ii) proximity of additional ligand enhances affinity through more
rapid association upon displacement of bound ligand.
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ence of 5% DMSO, resulting from dilution of the ligand stock
solution. When bound to mimetic 1 no significant changes
in the overall size or shape of hDM2 were observed, a small
peak at higher molecular weight also appears however, the
majority of the species observed can be assigned as mono-
meric hDM2. The molecular weights were characterised by
relating rate of sedimentation and diffusion coefficient to
buffer density and the partial specific volume occupied by
atoms in solution at a constant temperature, giving peaks as
14.5 kDa and 49.2 kDa for the major and minor peaks. The
molecular weight for the major peak is in the region expected
for hDM2 however the origin of the minor peak is unknown.
In the sample containing mimetic 2, a complete loss of the
peak for monomeric hDM2 was observed concomitant with
the appearance of higher order aggregates. The peak is incon-
sistent with the mass corresponding to a protein dimer, rather
it is the result of a much larger species. It is noteworthy that
aggregation by multivalent ligands is not unprecedented57 and
Scheme 1 Synthesis of helix mimetics 1 and 2.
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this unexpected result will be the focus of future investi-
gations. It is plausible that the dimeric mimetic 2 induces
protein dimerisation resulting in a ternary complex that is
capable of further aggregation although the possibility that the
mimetic is capable of interacting with additional binding sites
on hDM2 cannot be discounted. Such a scenario, need not
necessarily couple to the p53 tracer displacement occurring in
the fluorescence anisotropy experiment.
Conclusions
A novel helix mimetic dimer 2 was prepared using ‘click’ chem-
istry methodology. This dimeric ligand 2 was found to be a
potent inhibitor of the p53/hDM2 interaction being twice as
potent as the monomeric analogue 1. When considered in
terms of ligand copy number, 1 and 2 are similarly potent.
Despite this, more detailed modelling and experimentation
revealed the two compounds have differing modes of action.
Whilst monomeric ligand 1 favours 1 : 1 stoichiometry with
hDM2, compound 2 acts as a chemical inducer of dimeriza-
tion/aggregation. This suggests that, with further refinement,
such a strategy could be exploited for protein dimerisation
assisted inhibition of protein–protein interactions and in syn-
thetic biology58 for chemically induced dimerization59,60 and/
or the controlled assembly of proteins.61,62
Experimental
General considerations
All chemicals and solvents were purchased and used without
further purification. 1H, 13C and 2D NMR spectra were
recorded with a Bruker DRX 500 MHz or DPX 300 MHz
Fig. 2 Fluorescence anisotropy competition curves for the inhibition of
the p53/hDM2 interaction by the monovalent trimer 1 (black) and the
divalent trimer 2 (blue) in assay buffer (40 mM phosphate pH 7.5,
200 mM NaCl, 0.02 mg ml−1 BSA). hDM2 and FITC-p53 were added to a
dilution series of the mimetics to give final concentrations of 154.2 and
54.5 nM, respectively.
Fig. 3 Molecular modelling of compound 2; proposed binding mode of
compound 2 in the p53 binding cleft of two hDM2 molecules (PDB ID:
1YCR).
Fig. 4 hDM2 analysed by native PAGE in the presence of increasing
equivalent of both the monovalent ligand 1 (left) and divalent ligand 2
(right) run in 25 mM Tris buffer pH 8.6, 190 mM glycine. Bands were
visualised with Coomassie staining.
Fig. 5 Analytical ultracentrifugation analysis of hDM2 in the presence
of monomer 1 and dimer 2 at a 1 : 4 concentration ratio. Samples were
prepared in 40 mM phosphate buffer, 200 mM NaCl and 5% DMSO
where appropriate. Samples were centrifuged at 48 000 rpm and sedi-
mentation coefficients calculated.
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spectrometer. 1H NMR spectra are referenced to residual
solvent and chemical shifts are given as parts per million
downfield from TMS. Coupling constants are reported to the
nearest 0.1 Hz. IR spectra were recorded with a Perkin-Elmer
FTIR spectrometer and samples were analysed in the solid
phase. Mass spectra (HRMS) were obtained with a Bruker
maxis impact 3000 spectrometer using electrospray ionisation.
LC-MS experiments were run on a Waters Micromass ZQ
spectrometer. Analytical TLC was performed on 0.2 mm silica
gel 60 F254 pre-coated aluminium sheets (Merck) and visual-
ised by using UV irradiation. Flash chromatography was
carried out on silica gel 60 (35–70 micron particles, Fluoro-
Chem). The convention used to assign the spectroscopic data
and for naming compounds for this series of aromatic oligo-
amides has been described previously.37,56
Monomer syntheses and the synthesis of the monovalent
trimer have been reported previously.
Expression of hDM2 and fluorescence anisotropy assays
were performed as described previously.36,56
Synthesis of N-(N-(N-(benzyl-4-aminobenzoyl)-N-naphth-1-yl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine dimer
Glycine-loaded Wang resin (254 mg, 0.2 mmol) was swelled in
anhydrous DMF (5 ml) 15 minutes prior to reaction. The
monomers; benzyl (450 mg, 1.0 mmol), alkyne-1-naphthyl
(554 mg, 1.0 mmol) and isobutyl (415 mg, 1.0 mmol) were
each dissolved in anhydrous CHCl3 (10 ml) and pre-activated
for coupling with Ghosez’s reagent (630 μl, 20% in CHCl3,
0.96 mmol) for 1 hour at room temperature. The coupling reac-
tions were carried out on a CEM Liberty™ microwave assisted
automated peptide synthesiser. The trimer was then cleaved
from the resin with TFA–DCM (1 : 1, 1 ml) and analysed by
LC-MS to confirm formation of the desired trimer. The trimer
(25.7 mg, 0.033 mmol) was dissolved in THF–H2O (1 : 1, 10 ml)
and 1,11-diazido-3,6-9-trioxaundecance (3.47 μl, 0.017 mmol)
was added followed by CuSO4·5H2O (0.42 mg, 1.6 × 10
−3
mmol) and sodium ascorbate (0.43 mg, 3.3 × 10−3 mmol). The
reaction mixture was stirred overnight at room temperature.
The solvent was then removed and the residue taken up in
DMSO (5 ml) and any copper precipitate removed by centrifu-
gation. The DMSO was then removed under high vacuum
affording the desired compound as a sticky orange solid
(13.2 mg, 7.36 × 10−3 mmol, 43%). Rf = 0.3 (3 : 2, DCM–MeOH);
1H NMR (500 MHz, DMSO-d6) δ: 8.14–8.12 (m, 2–3°-T, 2H),
7.91–7.69 (br m, ArCH, 5H), 7.47–7.45 (m, ArCH, 4H),
7.27–7.05 (m, ArCH, 23H), 6.92–6.90 (m, 1-H2, 4H), 6.42–6.28
(m, 2-H5, 2-H6, 1-H3, 8H), 4.86–4.84 (s, 2-Hα, 4H), 4.55–4.53 (s,
1-NH, 2H), 4.26–4.24 (s, 4-Hα, 4H), 3.84–3.83 (s, 1-Hα, 4H), 3.64
(s, 3-Hα, 4H), 3.55–3.41(m, 2–3°-Hβ, 2–3°-Hγ, 2–3°-Hθ, 2–3°-Hι,
8H), 3.23 (s, 2–3°-Hδ, 2–3°-Hε, 2–3°-Hζ, 2–3°-Hη, 8H), 1.72–1.69
(m, 3-Hβ, 2H), 0.84 (s, 3-Hγ, 12H); HRMS: Calcd [M + H]+
(C104H105N14O15) m/z = 1789.787835, Found [M + H]
+ m/z =
1789.785716; νmax (cm−1): 3319s (O–H), 2916s (C–H), 1635s
(CvO), 1601s (CvO), 1504s, 1418m, 1385m, 1338w, 1284s,
1182m, 1130s, 1017s.
Molecular modelling
The protein structure for hDM2 (PDB ID: 1YCR) was prepared
using the protein preparation wizard within Maestro (Schro-
dinger) and the docking grid prepared by selecting the binding
groove of the p53 helix using Glide (Schrodinger).
The monovalent inhibitor was docked using Glide (Schro-
dinger) and these docked structures superimposed onto a low
energy structure of the divalent inhibitor to provide a model of
protein dimerization.
Native PAGE
Protein samples were separated on a 10% acrylamide native
PAGE gel in 25 mM Tris, 190 mM glycine buffer pH 8.6, gel
was run at 25 mA. Bands were visualised with Coomassie stain-
ing. Samples were diluted from 10 mM DMSO stocks into
50 mM Tris buffer pH 8.0, 200 mM NaCl, 0.5 mM DTT.
Sedimentation velocity analytical ultracentrifugation
Samples (0.32 ml) were placed in a 1.2 cm pathlength 2-sector
meniscus-matching epon centrepiece cell constructed with
sapphire windows and centrifuged at 48 000 rpm in an An50-Ti
rotor in an Optima XL-I analytical ultracentrifuge at 20.0 °C.
Changes in concentration of the solute were detected by inter-
ference optics, with a total of 500 scans being taken over
approximately 8.3 hours. Buffer densities and viscosities were
calculated by Sednterp version 1.09, omitting the presence of
5% DMSO.63 Radial interference profiles were fitted using the
program Sedfit version 12.1b using a continuous distribution
c(S) Lamm equation model.64
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